Tatva chintan share

Tatva Chintan Pharma Chem Ltd., incorporated in the year 1996, is a Small Cap company (having a market cap of Rs 5520.87 Crore) operating in General sector. Tatva Chintan Pharma Chem Ltd. key Products/Revenue Segments include Speciality Chemicals, Other Operating Revenue, Scrap and Duty Drawback for the year ending 31-Mar-2021. For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 126.42 Crore, up 15.14 % from last quarter Total Income of Rs 109.80 Crore and unchanged .00 % from last year same quarter Total Income of Rs Crore. Company reported net profit after tax of Rs 32.41 Crore in latest quarter. (Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.

Dublin, June 14, 2023 (GLOBE NEWSWIRE) -- The ResearchAndMarkets.com's offering. The global market for Ionic Liquids estimated at US$38.4 Million in the year 2022, is projected to reach a revised size of US$63.5 Million by 2030, growing at a CAGR of 6.5% over the analysis period 2022-2030. Solvents & Catalysts, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$20.3 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Batteries & Electrochemistry segment is readjusted to a revised 6.9% CAGR for the next 8-year period. The U.S. Market is Estimated at $10.5 Million, While China is Forecast to Grow at 10.5% CAGR The Ionic Liquids market in the U.S. is estimated at US$10.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$14.4 Million by the year 2030 trailing a CAGR of 10.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 6.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.7 Million by the year 2030. Select Competitors (Total 38 Featured) - • BASF SE • Evonik Industries AG • Merck KgaA • Proionic GmbH • Reinste Nano Ventures Pvt., Ltd. (RNV) •...

Tatva Chintan Pharma Chem Ltd. is a chemicals manufacturing company. The firm is engaged in the manufacture of portfolio, which includes structure directing agents(SDAs), phase transfer catalysts(PTCs), electrolyte salts for super capacitor batteries, and pharmaceutical and agrochemical intermediates and other specialty chemicals(PASC). The company was founded on June 12, 1996 and is headquartered in Ankleshwar, India. In the Weekly chart of TATVA , We can see that, it is holding strongly at 2000-2050 levels. Lets see if it makes an uptrend or we will see new Lows below 2000 levels. In the Weekly chart of TATVA , We can see that, it is holding strongly at 2000-2050 levels. Lets see if it makes an uptrend or we will see new Lows below 2000 levels. Buying zones buys small small quantities if next q give good result seems on 3000 level asap. No. Eq. Shares Cr 2.22 ---------- Promoters+ - FIIs +- DIIs + Public + sep 2021 79.17 3.53 7.36 9.94 Dec 2021 79.17 2.91 7.87 10.05 Mar 2022 79.17 3.05 8. Buying zones buys small small quantities if next q give good result seems on 3000 level asap. No. Eq. Shares Cr 2.22 ---------- Promoters+ - FIIs +- DIIs + Public + sep 2021 79.17 3.53 7.36 9.94 Dec 2021 79.17 2.91 7.87 10.05 Mar 2022 79.17 3.05 8.

The specialty chemicals company Tatva Chintan Pharma Chem's Rs 500-crore public issue received overwhelming response from investors as it was oversubscribed by 180.36 times during July 16-20, the second highest subscription in 2021 after MTAR Technologies. Non-institutional investors put in bids 512.22 times their reserved portion, while the portion set aside for qualified institutional buyers was subscribed 185.23 times and that of retail 35.35 times. Once the allotment is finalised, it can be checked either on BSE website or IPO registrar. On the IPO registrar website, which is Link Intime, investors have to first select company name - Tatva Chintan Pharma Chem Limited, in the dropdown menu in the Select company field. Then choose between PAN Number or Application Number or DP/Client ID or Account No/IFSC. After adding the details of the opted document, click on Submit to know the application status. On the BSE website, one has to first select Equity in the Issue type field. In the Issue Name field, select Tatva Chintan Pharma Chem. Then enter your Application Number and PAN Number, and finally click on the Search button. The offer comprised a fresh issue of Rs 225 crore and an offer for sale of Rs 275 crore by existing selling shareholders. The net proceeds from fresh issue will be utilised for expansion of Dahej manufacturing facility; upgradation of R&D facility in Vadodara; and general corporate purposes. To Know All IPO Related News, Click Here And finally the s...

Tatva Chintan Pharma Chem shares consistently witnessed buying interest as it was trading more than 110 percent in the afternoon on July 29. At 14:52 hours IST, it was quoting at Rs 2,325, up 10.10 percent compared to opening price and up 114.68 percent compared to issue price on the BSE. It saw trading volume of 8.68 lakh equity shares. 12:48 PM - Update Tatva Chintan Pharma Chem shares continued to see strong demand from investors as it is still trading at more than 100 percent premium. At 12.48 hours IST, it was quoting at Rs 2,276, up 110.16 percent on the BSE, with volume of 6.86 lakh equity shares. 10:45 AM - Update Tatva Chintan Pharma Chem shares extended rally after stellar debut, rising as much as 129.6 percent to hit a day's high of Rs 2,486.30 on the BSE. At 10:45 hours IST, it was trading at Rs 2,287.95, up by Rs 176.15 or 8.34 percent over opening price and up by Rs 1,204.95 or 111.26 percent over issue price of Rs 1,083, with volume of 3.97 lakh equity shares. 10:00 AM - Opening Trade Tatva Chintan Pharma Chem shares had a blockbuster debut at 95 percent premium on the BSE, meeting analysts' expectations and grey market premium, on July 29. The stock opened at Rs 2111.80, compared to the issue price of Rs 1,083. The Rs 500-crore public issue of the specialty chemical company got a healthy response from investors, as it was subscribed 180.35 times during July 16-20. The portion set aside for qualified institutional buyers was subscribed 185.23 times, non-inst...

Tatva Chintan Pharma Chem Limited (commonly known as Tatva Chintan) is a leading specialty chemicals manufacturing company in India. Since its inception in 1996, Tatva Chintan has successfully established an integrated model comprising of world class manufacturing infrastructure, multiple complex chemical processes, warehousing facilities, and technically sound R&D and Analytical capabilities. We take pride in our highly efficient operations, superior quality products, cutting edge innovation and technology exploration, and our long term focus on sustainability.

Specialty chemical company Tatva Chintan Pharma Chem shares traded at more than 100 percent premium in the grey market on July 27, ahead of listing later this week. The stellar IPO subscription, leading position in manufacturing of structure-directing agents for zeolites in India, healthy financials and return ratios, and high quality product portfolio could be key reasons for hefty grey market premium. Tatva Chintan shares traded at a premium of Rs 1,000-1,100/share in the grey market, the IPO Watch and IPO Central showed. This resulted into a price of Rs 2,083-2,183, a premium of 92.3 percent - 101.6 percent over expected final issue price of Rs 1,083 per share. The grey market is an unofficial platform, wherein IPO shares traded till the listing of a company on the bourses. Equity shares will make a debut on the bourses on July 29. The Rs 500-crore public issue of Tatva Chintan was oversubscribed by 180.36 times during July 16-20 following strong response from all kind of investors. Non-institutional investors have put in bids 512.22 times their reserved portion and qualified institutional buyers 185.23 times, while the portion set aside for retail investors was subscribed 35.35 times. The offer comprised a fresh issue of Rs 225 crore and an offer for sale of Rs 275 crore by existing selling shareholders. The net proceeds from fresh issue will be utilised for expansion of Dahej manufacturing facility; and upgradation of R&D facility in Vadodara. Also read: Tatva Chi...